Furthermore, GLP-1 receptor agonists (GLP-1RAs) represent an exciting avenue for sepsis management, not only through their metabolic benefits in obesity and type 2 diabetes but also by their ability to elevate adiponectin levels. This evidence concerns the gene ADIPOQ and obesity due to melanocortin 4 receptor deficiency.